MASTERINVEST Kapitalanlage GmbH Makes New Investment in Boston Scientific Corporation $BSX

MASTERINVEST Kapitalanlage GmbH bought a new position in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 66,131 shares of the medical equipment provider’s stock, valued at approximately $2,822,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Kelleher Financial Advisors purchased a new position in Boston Scientific in the 2nd quarter valued at approximately $25,000. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth $26,000. Swiss RE Ltd. purchased a new stake in shares of Boston Scientific during the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC bought a new position in shares of Boston Scientific in the fourth quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new position in shares of Boston Scientific in the first quarter valued at $28,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 3.2%

Shares of NYSE BSX opened at $46.64 on Friday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The business has a 50-day moving average of $46.53 and a 200-day moving average of $56.72. The firm has a market capitalization of $67.59 billion, a price-to-earnings ratio of 18.88, a PEG ratio of 1.05 and a beta of 0.56. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period last year, the firm posted $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its board has initiated a share repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s management believes its shares are undervalued.

Analysts Set New Price Targets

A number of analysts recently issued reports on BSX shares. Raymond James Financial reissued an “outperform” rating and set a $57.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Evercore set a $65.00 target price on Boston Scientific in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $60.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Truist Financial cut their price objective on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, Royal Bank Of Canada decreased their price target on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Director Susan E. Morano reportedly purchased additional Boston Scientific shares, signaling confidence from an insider while the stock is near its recent lows. Top Boston Scientific Insider Makes Bold New Share Grab
• Neutral Sentiment: The company’s latest quarterly results had been stronger than expected, with adjusted EPS and revenue exceeding consensus estimates and revenue rising year over year. However, that earnings momentum may provide limited near-term support while the cyber incident remains unresolved.
• Negative Sentiment: Boston Scientific said the cyberattack disrupted information systems used to process customer orders and ship products worldwide. The company is working to restore access, but the timing of a full recovery remains unclear, raising the risk of shipment delays, lost sales, remediation costs and weaker near-term results. Boston Scientific hit by cyberattack, global operations affected
• Negative Sentiment: The cybersecurity disruption comes alongside reports of a cardiac-device recall, increasing investor concerns about operational reliability, regulatory exposure and pressure on Boston Scientific’s growth outlook. The company has not yet quantified the financial impact of either issue. Boston Scientific hit with cardiac device recall

Insider Activity

In related news, Director Edward J. Ludwig acquired 5,000 shares of the stock in a transaction dated Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael F. Mahoney acquired 186,240 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.